Ocugen (OCGN) Cash from Investing Activities (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.86% |
| Dec 31, 2025 | 59.30% |
| Sep 30, 2025 | 2.27% |
| Jun 30, 2025 | 13.73% |
| Mar 31, 2025 | -684.62% |
| Dec 31, 2024 | 97.44% |
| Sep 30, 2024 | 1.17% |
| Jun 30, 2024 | 78.19% |
| Mar 31, 2024 | 13.59% |
| Dec 31, 2023 | 19.11% |
| Sep 30, 2023 | -158.80% |
| Jun 30, 2023 | 66.32% |
| Mar 31, 2023 | 122.50% |
| Dec 31, 2022 | -18,327.71% |
| Sep 30, 2022 | 93.92% |
| Jun 30, 2022 | -512.56% |
| Mar 31, 2022 | -16.15% |
| Dec 31, 2021 | 45.14% |
| Sep 30, 2021 | 65.45% |
| Jun 30, 2021 | -288.12% |
| Mar 31, 2021 | -3.98% |
| Dec 31, 2020 | -1,040.91% |
| Sep 30, 2020 | -215.79% |
| Jun 30, 2020 | 135.85% |
| Mar 31, 2020 | -153.95% |
| Dec 31, 2019 | 99.05% |
| Sep 30, 2019 | -1,714.25% |
| Jun 30, 2019 | -1,048.15% |
| Sep 30, 2018 | 218.77% |
| Jun 30, 2018 | -316.62% |
| Mar 31, 2018 | -147.52% |
| Dec 31, 2017 | -87.76% |
| Sep 30, 2017 | 16,163.16% |
| Jun 30, 2017 | 99.53% |
| Mar 31, 2017 | -268,000.00% |
| Dec 31, 2016 | 0.00% |
| Sep 30, 2016 | 98.94% |
| Jun 30, 2016 | -781.25% |
| Mar 31, 2016 | 75.57% |
| Dec 31, 2015 | 73.69% |
| Sep 30, 2015 | -22.96% |
| Jun 30, 2015 | 55.74% |
| Mar 31, 2015 | 47.53% |
| Dec 31, 2014 | -26.01% |
| Sep 30, 2014 | -1,795.89% |
| Jun 30, 2014 | 39.17% |